Risk-reducing strategies #1
In patients with breast cancer with a population risk of contralateral breast cancer (that is, no genetic predisposition) do not routinely offer risk-reducing mastectomy for the contralateral breast.
In the general population, there is no evidence that a contralateral risk reducing mastectomy improves a patient’s prognosis. However, a contralateral risk reducing mastectomy may be undertaken to address specific patient concerns if it is discussed at a multidisciplinary team meeting and the benefits, risks and alternatives have been discussed with the patient
A body of evidence including studies rated a 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
How this guidance was developed
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded 'B' (using SIGN methods) by the source guideline authors. The source recommendation was adapted by removing 'if it is discussed at a multidisciplinary team meeting' as this does not always happen in practice. The recommendation was made more directive by adding ‘do not routinely offer’.
Risk-reducing strategies #1
In patients with breast cancer with a population risk of contralateral breast cancer (that is, no genetic predisposition) do not routinely offer risk-reducing mastectomy for the contralateral breast.
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded 'B' (using SIGN methods) by the source guideline authors. The source recommendation was adapted by removing 'if it is discussed at a multidisciplinary team meeting' as this does not always happen in practice. The recommendation was made more directive by adding ‘do not routinely offer’.